The Use of a Translucent dCHPM Allograft on Bilateral Chronic Ablation Wounds
View Report
A Translucent Dehydrated Complete Human Placental Membrane (dCHPM) Allograft
Enverse allografts are designed to be used as a wound covering or barrier membrane over chronic and acute wounds. Through the patented Clearify® technology, all three layers of the native placental membrane (amnion, intermediate layer, and chorion) are retained. The native layers are never separated during processing, which allows for optimal preservation of key structural proteins and components.1
Case Reports
Anterior Lumbar Two-Level Fusion with Placement of Translucent dCHPM Allograft
The Use of a Translucent dCHPM Allograft on Bilateral Chronic Ablation Wounds
Common Clinical Applications
- Amputations
- Diabetic Ulcers
- Hysterectomies
- Lumbar & Cervical Fusions
- Myomectomies
- Pressure Ulcers
- Surgical Wounds
- Tendon & Ligament Repairs
- Traumatic Wounds
- Venous Ulcers
*Enverse is intended to be used as a wound covering or barrier membrane.
†Enverse complements standard of care as a barrier membrane following primary repair or closure.
- General Surgery
- Infectious Disease
- OBGYN
- Orthopedics
- Plastic Surgery
- Podiatry
- Spine
- Urology
- Vascular Surgery
Common Anatomical Applications
Sizes & SKUs
| Size | 15 mm disk | 2 x 3 cm | 4 x 4 cm | 4 x 6 cm | 6 x 8 cm |
|---|---|---|---|---|---|
| SKU | EN-0015 | EN-2030 | EN-4040 | EN-4060 | EN-6080 |
Sheet Format | Shelf-stable for up to five (5) years
Related Resources
1. Data on file.
2. Data is compared to the leading dual-layer allograft.
3. De Silva, G. S., Saffaf, K., Sanchez, L. A., & Zayed, M. A. (2018). Amputation stump perfusion is predictive of post-operative necrotic eschar formation. American journal of surgery, 216(3), 540–546.
4. Frykberg RG, Banks J. Challenges in the Treatment of Chronic Wounds. Adv Wound Care (New Rochelle). 2015 Sep 1;4(9):560-582. doi: 10.1089/wound.2015.0635. PMID: 26339534; PMCID: PMC4528992.
5. Winkley, K., Sallis, H., Kariyawasam, D., Leelarathna, L. H., Chalder, T., Edmonds, M. E., Stahl, D., & Ismail, K. (2012). Five-year follow-up of a cohort of people with their first diabetic foot ulcer: the persistent effect of depression on mortality. Diabetologia, 55(2), 303–310. https://doi.org/10.1007/s00125-011-2359-2
6. Jeyaraman, K., Berhane, T., Hamilton, M., Chandra, A. P., & Falhammar, H. (2019). Mortality in patients with diabetic foot ulcer: a retrospective study of 513 cases from a single Centre in the Northern Territory of Australia. BMC endocrine disorders, 19(1), 1. https://doi.org/10.1186/s12902-018-0327-2
7. Amadou, C., Carlier, A., Amouyal, C., Bourron, O., Aubert, C., Couture, T., Fourniols, E., Ha Van, G., Rouanet, S., & Hartemann, A. (2020). Five-year mortality in patients with diabetic foot ulcer during 2009-2010 was lower than expected. Diabetes & metabolism, 46(3), 230–235. https://doi.org/10.1016/j.diabet.2019.04.010
Patents: www.stimlabs.com/patents
© 2023 Stimlabs® LLC; STIMLABS, REVITA, COGENEX, ENVERSE, VIALIZE, RELESE, and CLEARIFY are trademarks of Stimlabs LLC.
